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Abstract
The term astrocytoma defines a quite heterogeneous group of neoplastic diseases that collectively represent the most
frequent brain tumors in humans. Among them, glioblastoma multiforme represents the most malignant form and its
associated prognosis is one of the poorest among tumors of the central nervous system. It has been demonstrated that a
small population of tumor cells, isolated from the brain neoplastic tissue, can reproduce the parental tumor when
transplanted in immunodeficient mouse. These tumor initiating cells are supposed to be involved in cancer development
and progression and possess stem cell-like features; like their normal counterpart, these cells remain quiescent until they are
committed to differentiation. Many studies have shown that the role of the tumor suppressor protein PTEN in cell cycle
progression is fundamental for tumor dynamics: in low grade gliomas, PTEN contributes to maintain cells in G1 while the
loss of its activity is frequently observed in high grade gliomas. The mechanisms underlying the above described PTEN
activity have been studied in many tumors, but those involved in the maintenance of tumor initiating cells quiescence
remain to be investigated in more detail. The aim of the present study is to shed light on the role of PTEN pathway on cell
cycle regulation in Glioblastoma stem cells, through a cell differentiation model. Our results suggest the existence of a
molecular mechanism, that involves DUB3 and WEE1 gene products in the regulation of Cdc25a, as functional effector of the
PTEN/Akt pathway.
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Introduction
Glioblastoma multiforme (GBM) is the most malignant form of
glioma and its associated prognosis is one of the poorest among
tumors of the central nervous system (CNS). It has been recently
demonstrated that a small population of tumor cells, with stem
cell-like features (GSCs), can initiate tumor development in vivo
and are thought to be involved in tumor maintenance and
diffusion [1,2]. These cells, as well as their normal counterparts,
tightly regulate their growth while uncommitted but quickly gain
uncontrolled proliferation as soon as they are committed to
differentiate. Molecular switches underlying these phenomena are
tightly linked to the features of disease development and
progression.
It has been shown that the tumor suppressor protein PTEN is
involved in cell cycle regulation, through the modulation of
different signaling pathways, either in cancer in general and in
brain tumor in particular [3,4,5]. The functional role of PTEN in
brain cancers progression seems to be tightly linked to tumor
dynamics: in low grade gliomas, PTEN contribute to maintain
cells in G1 while the loss of its activity is frequently observed in
high grade gliomas [4]. One of the most characterized
downstream effectors of PTEN is Akt [6]. In particular, many
studies investigating the PTEN-dependent cell cycle regulation,
reported the the influence of PTEN/Akt signaling pathway on
post-translational activation and stability of cell cycle regulatory
proteins [7,8]. To identify downstream molecular actors involved
in PTEN mediated cell cycle modulation, a prostatic cancer
cellular model expressing PTEN cDNA was recently used [9].
This modification led to a significant inhibition of cell proliferation
due to cycle arrest in the G1 phase. Gene expression analysis
subsequent to PTEN reintroduction, coupled with phosphoryla-
tion status of downstream molecular targets, suggest that PTEN
physiologically regulates cell cycle related proteins, through pAKT
dependent and independent ways. E2F2, cdc25a, Cyclin G2 and
RBL2 proteins are among them [9,10].
The aim of the present study was to shed light on the role of
PTEN pathway on cell cycle regulation in GSCs through a cellular
differentiation model. Phosphoproteomics profiling of different
GSCs lines, using reverse phase protein microarrays (RPMA),
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indicates a heterogeneous basal activity of PTEN and related
molecules. Transcriptomics profiling of GSCs induced to differ-
entiate demonstrates specific molecular changes in PTEN positive
cells, that are not observed in cells lacking its activation. The most
modulated transcripts suggest a post-transcriptional regulation
model, which involves cdc25a as the main target.
Materials and Methods
Ethics statement
This study has been approved by Institute of Neurosurgery,
Catholic University School of Medicine, Rome, Italy. Before
surgery patients provided written consent.
Patients, diagnosis, and tumor characterization
Tumor tissue samples were collected from 8 patients with
primitive brain tumor undergoing complete or partial surgical
resection at the Institute of Neurosurgery, Catholic University
School of Medicine, in Rome, Italy. A diagnosis of glioblastoma
multiforme, established histologically according to the WHO
classification [11], was the eligibility criteria. Patients character-
istics are summarized in table 1. Tumor samples were obtained
by complete or partial resection before the initiation of treatment
with radiation and chemotherapy. The expression of both the
proliferation marker Ki-67 and of tumor protein 53 (P53) were
characterized on tumor specimen by immunohistochemistry on
deparaffinized sections using the avidin-biotin-peroxidase com-
plex methods (ABC-Elite kit, Vector Laboratories, anti-Ki67
monoclonal antibody (MIB-1, Dako), anti-p53 monoclonal
antibody (DO-7, Dako) and anti-epidermal growth factor
receptor (EGFR) monoclonal antibody (EGFR.25, Novocastra).
Tumors were considered p53 deficient if immunoreaction stained
the nuclei of less than 5% of cells [12,13]. Tumors showing
moderate-to-strong immunostaining for EGFR in .20% of cells
were considered EGFR positive [14]. O6-methylguanine-DNA
methyltransferase (MGMT) promoter methylation patterns were
assessed on genomic DNA extracted from paraffin-embedded
tissue by methylation-specific: it has been shown that the DNA
repair protein MGMT influence the resistance of glioblastoma
cells to alkylating agents, such as nitrosoureas and temozolomide
thus representing and important prognostic and therapeutic
indicator [15].
Cell culture and neural differentiation
GSCs were obtained from freshly dissociated surgical specimens
cultivated in a serum-free medium containing epidermal growth
factor (EGF) and basic fibroblast growth factor (FGF), as
previously described [16,17,18]. In these conditions, cells grow
as clusters of undifferentiated cells (neurospheres). For the
differentiation protocol, 56105 cells were plated in matrigel
(1:25 in stem cell medium) coated flasks and induced by growth
factors deprivation and supply of 5% serum in the growth
environment. After 14 days, cells were checked for differentiation
markers by flow cytometry and for cellular morphology. Cyto-
fluorimetric analysis was performed using a FACS Canto flow
cytometer (Becton Dickinson) to assess the expression of CD133,
Sox2 and nestin (NES), as stem cells markers, and glial fibrillary
acidic protein (GFAP) and beta 3 tubulin (TUBB3), as differen-
tiation markers (Miltenyi Biotec antibodies). Cellular immuno-
phenotype was also assessed by means of a laser confocal
microscope (Leica TCS SP5, Leica Microsystem S.p.A.). Primary
antibodies against Sox2, GFAP (both from Cell Signaling
Table 1 Patients characteristics.
Sample sex Age (yr) KPS (score)
Symp.
(mo.) Location ki 67 (%) p53 MGMT EGFR PFS OS PTEN activ
a M 40 80 2.5 Temporal 20 + + + 6.0 12.5 low
b M 77 80 2 Parietal 50 + 2 + 1.0 2.0 high
c M 72 90 1.5 Frontal 5 2 + 2 6.0 11.5 high
d M 44 80 1 Frontal 10 2 + + 5.0 7.5 low
e M 59 80 2 Occipital 35 + 2 + 3.0 6.0 low
f M 48 60 2.5 Parietal 20 + 2 + 1.0 2.0 high
g M 58 70 3 Parietal 10 2 2 2 4.0 10.5 high
h M 52 70 0.5 Temporal 40 + 2 + 3.0 8.0 high
Characteristics of patients from which samples were collected. Legend: Sample = sample identifier, sex = patient sex, KPS (score) = Karnofsky Performance Status
score; Sympt. (mo) = symptom duration in month; Surgery (type) = origin of tumor tissue from the patient brain (temporal/parietal/occipital/frontal); ki67-% =% of
cells expressing ki-67; p53 = p53 positivity (less than 5% of nuclei); MGMT = MGMT promoter metylation; EGFR = EGFR positivity (moderate-to-strong signal on .% of
cells); PFS = progression-free survival; OS = overall survival; PTEN activ = PTEN activation group according to clustering of phospoproteomics profiles.
doi:10.1371/journal.pone.0081432.t001
Figure 1. Immunophenotype of undifferentiated and differen-
tiated cells. Immunofluorescence of undifferentiated GSCs neuro-
sphere (left panels) and of differentiated cells (right panels) labelled
with anti-human Sox2 (top panels), anti-human GFAP and anti-human
TUBB3 (bottom panels).
doi:10.1371/journal.pone.0081432.g001
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Technology) and TUBB3 (Millipore) were diluted in 1% BSA to a
final concentration of 5 mg/ml and incubated for 1 h.
Reverse phase protein arrays
RPPA was performed as previously described [19]. Samples
were lysed using Tissue Protein Extraction Reagent (Thermo
Scientific, Waltham, MA, USA) and diluted up to 0.5 mg/mL
with Novex Tris-Glycine SDS Sample Buffer 2X (Invitrogen
Corporation, Carlsbad, CA, USA). Each lysate was spotted in a
two-fold 5 point dilution curve onto nitrocellulose-coated micro-
scope slides using an Aushon Arrayer 2470 (Billerica, MA, USA)
and slides underwent incubation with a single validated primary
antibody using DAKO Autostainer Plus (DAKO Corporation,
Glostrup, Denmark). Total protein quantification was performed
using Sypro Ruby Protein Staining solution (Invitrogen) and slides
were scanned using a Vidar Revolution 4200 microarray scanner
(Vidar Systems Corporation, Herndon, VA, USA). Antibody slides
were scanned using a flatbed scanner and raw images were
processed for secondary antibody subtraction and normalization to
total protein.
Gene expression profiling
Samples transcriptomes were characterized using Affymetrix
GeneChip Human Gene 1.0 ST arrays. Total RNA was extracted
and processed according to manufacturer procedures. CEL files
were quality checked, acquired and processed using Affymetrix
Power Tools with RMA normalization option. Preprocessed data
are available as file S1.
Statistical analysis and functional annotations
PTEN positive and PTEN negative groups of samples were
defined using unsupervised hierarchical clustering of three
dimensional (PTEN, AKT and pAKT) protein expression
profiles. Euclidean metric was used for distance calculations.
Differences in gene expression profiles were evaluated using
paired t test (95% confidence intervals, a=0.05). Association
between gene expression levels of candidate transcripts and PFS
Figure 2. Protein expression profiles of GSC samples. (A) PTEN, (B) AKT, (C) pAKT and (D) pAKT/AKT proteins expression profiles in different
lines of GSCs. Bars are coloured according to groups previously defined using hierarchical clustering of protein profiles: white bars are used for PTEN
negative cell lines while grey bars for PTEN positive.
doi:10.1371/journal.pone.0081432.g002
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or OS were assessed using a Cox proportional hazards regression
model. Clustering, plots and t statistics were produced using R
statistical environment [20].
Results
Differentiation
14 days after induction, differentiated cells show glial fibrillary
acidic protein (GFAP) and beta 3 tubulin (TUBB3), while they lose
the expression of CD133, Sox2 and nestin (NES) when assessed by
cytoflourimetry. During the induction, cells proliferate to reach a
count of 2,5 millions on average.
Neurospheres show the expression of Sox2 while differentiated
cells, which lack its expression, show the expression of the
differentiation markers GFAP and TUBB 3 (Figure 1).
Phosphoproteomics
The analysis of phosphoproteomics profiles shows that GSCs
may present differences, in basal conditions, in the activation
status of PTEN pathway. Its global activity has been checked by
measuring the protein expression levels of PTEN and of its
downstream molecular partner AKT, which behaviour can be
regulated by specific phosphorylation events. In particular, we
analyzed the presence of activatory S473 phosphoepitope of AKT.
Three cell lines (a, d and e) showed proteins profiles which are
Figure 3. Transcripts fold change in differentiation. Green, red
and black indicate transcripts that decrease, increase or maintain their
concentration during induction respectively.
doi:10.1371/journal.pone.0081432.g003
Figure 4. Transcriptional and post-translational modulation of CDC25A, DUB3 and Wee1 during cell cycle in PTEN active cell lines.
CDC25A mRNA is constantly produced throughout all phases while DUB3 expression increases in the G1/S phase and wee1 expression decreases
during the phase M. CDC25A modulation occurs at post translational level with DUB3 inhibiting its ubiquitination and Wee1 controlling negatively
the activity of Cyclin-B/Cdk1.
doi:10.1371/journal.pone.0081432.g004
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related to the lack of PTEN pathway activity (low PTEN and
positive signal for the active phosphothreonine AKT form) while
all the other lines showed profiles which indicate PTEN pathway
activation (figure S1). According to these observation PTEN
positive and PTEN negative cell lines were defined (Figure 2).
Samples were grouped according to the above-described
molecular criterion and cells were induced to differentiate. Gene
expression profiles in both groups were analyzed comparing
differentiated and undifferentiated samples, in order to identify
transcripts that are specifically modulated during differentiation.
Profiles were analyzed comparing each differentiated sample with
its corresponding baseline; then, transcripts that showed a
statistically significant modulation in a paired test were selected.
Transcripts having less than 2 fold of modulation in logarithmic
scale in more than 30% of samples were discarded because the
overall intensity of variation wasn’t considered relevant in sample
population. Results are presented in figure 3. In general, cells
induced to differentiate show a positive regulation of deubiquiti-
nating enzyme 3 (DUB3), thrombospondin 1 (THBS1), Leucine
Rich repeat neuronal 1 (LRRN1) and Secreted Frizzled related
protein 4 (SFRP4) transcripts and a negative regulation of Wee1,
miR 21, Sprouty homolog 4 (SPRY4), Sprouty homolog 1
(SPRY1), Dual specificity phosphatase 6 (DUPS6), Dual specificity
phosphatase 4 (DUSP4) ones.
These transcripts showed no significant associations between
expression levels and patients or specimen characteristics (location,
surgery type, ki 67%, p53 positivity, MGMT, EGFR, PFS, OS).
Differences in PTEN active and inactive groups
When PTEN active and inactive cell lines are compared,
differences are observed in the extent of modulation observed in
previously selected transcripts. While Dub3 and mir21 are
significantly modulated (with upregulation and downmodulation
respectively) in PTEN active cell lines, their transcripts variation is
far less evident than in PTEN inactive ones. Wee1 is significantly
downmodulated in both groups.
Discussion
Stem cells tightly regulate cell cycle progression in order to
remain quiescent inside their cellular niche with progress
occurring only when external stimuli indicates the need for cell
growth or for the replacement of damaged or senescent cells.
This process is so crucial that involved molecules are subjected to
multiple levels of regulation. Cell-cycle transitions can be often
the results of coordinate factors which involves rapid turnover of
crucial regulatory proteins through the ubiquitin-proteasome
system. These mechanisms are shown to be frequently altered
when observing cancer cell proteomes, and dysregulation of these
pathways is clearly linked to the acquisition of neoplastic
phenotype.
A paradigmatic example is represented by the cell division cycle
25A (Cdc25A) protein, which is often found expressed in high
concentration in many cancers [21,22,23]. No genetic amplifica-
tion events or stabilizing mutations have been reported in
literature for Cdc25a, suggesting that its modulation in tumors
could be due to different regulatory mechanisms. Pereg and
colleagues [24] defined a simple circuit of Cdc25a post transla-
tional regulation in breast cancer cell, starting from the
observation that there is no significant correlation between
Cdc25A mRNA and protein levels [25]. According to this model
even if Cdc25a mRNA is constantly expressed during each of the
cell-cycle stages, its protein level is kept low during G1 by
proteasomal degradation that follows the ubiquitination operated
by APC protein. DUB3 acts as an inhibitor of Cdc25a
ubiquitination thus providing stability to it. DNA damage
checkpoints proteins contribute to Cdc25 protein modulation,
during S phase, though the activation of SCFb-TRCP-dependent
turnover (which also rely on Cdc25a ubiquitination). DUB3 can
interfere with this process also inhibiting ubiquitin flagging of
Cdc25a. During mitosis, Cdc25 protein is stabilized by the
complex Cyclin-B/Cdk1 through phosphorylation. This post-
translational stabilization is negatively controlled by the Wee1
kinase, which can inhibit Cyclin-B/Cdk1 activity.
By comparing GSCs to the differentiated counterparts, we
observed that transcripts levels of Cdc25a, APC protein complex,
SCF protein complex and Cyclin-B/Cdk1 do not vary after
differentiation. Conversely, DUB3 mRNA is strongly upmodu-
lated in differentiation and this could promote cell cycle
progression, with the stabilization of Cdc25a, even in presence
of DNA damage. Coherently, Wee1 appears to be one of the most
downregulated genes, suggesting the release of Cyclin-B/Cdk1
from its inhibitory control, thus triggering the activation of Cdc25a
in mitosis. Furthermore, it is interesting to observe that the mature
form of miR-21 appears to be one of the RNAs that significantly
fade during differentiation. miR-21 has been observed to target
directly cdc25a in human cancer cells [26]. As above mentioned,
Cdc25a mRNA levels are not influenced by the induction, while a
post-transcriptional regulation, operated by a microRNA, should
be reflected on its target transcript, at least partially. If the
suggested post-transcriptional mechanism is actually involved in
cell cycle regulation in GSCs, it probably occurs through the
inhibition of translation instead of target mRNA degradation. A
description of the involved actors and their variations through the
induction of differentiation in GSC is schematized in figure 4.
According to that observed in PTEN positive GSCs, we propose
a model in which Cdc25a is persistently transcribed during each of
the cell cycle phases. In GSCs, its corresponding protein level is
negatively regulated by its post-translational regulators, which
contribute to maintain cells in interphase. The initial phase of the
commitment to differentiation is the release from cell cycle
progression control by the inhibition of cdc25a degradation by the
activity of the augmented concentration of Dub3. This protein
counteracts both the effects of APC/Cdh1 and of ubiquitination
triggered by DNA damage checkpoints, providing cells the ability
to progress through S and G2 phases. The stabilization of cdc25a
through G2 and mitosis is also permitted by the diminished
inhibitory effect of Wee1, which is strongly downregulated in
differentiation, on Cyclin-B/Cdk1 complex. The downmodulation
of miR-21 likely contributes also to the overall increase in cdc25a
protein level by removing the post-transcriptional inhibition based
on translation efficiency.
In this model, Dub3 and Wee1 are involved in cell cycle
regulation in a cellular phenotype specific way. Dub3 promotes
cell cycle progression in committed cells, although its transcript
level remains low in stem cells. Conversely, Wee1 resulted
expressed in stem cells, suggesting that its activity provide the
ability to avoid G2/M transition.
While recent literature [24,27] indicates Dub3 as an eligible
therapeutic target for cancers expressing Cdc25a, our results imply
that its inhibition may be ineffective in tumor initiating cells, which
actually don’t rely on Dub3 function. Moreover, therapeutic
agents that can influence proliferation or survival of differentiated
tumor cells may actually act in positive selection of GSCs from the
tumor mass and remain ineffective in targeting cells that are able
to promote neoplastic diffusion and disease recurrence. For this
reason a deep understanding of molecular events underlying cell
DUB3 and WEE1 Regulate cdc25a il Glioblastoma CSC
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cycle regulation in PTEN-positive GSCs is fundamental in order
to develop new effective therapies for glioblastoma treatment.
Supporting Information
Figure S1 Hierarchical clustering of samples according
to their mean PTEN, AKT and pAKT protein expression
levels.
(TIFF)
File S1 Table reporting whole genome transcriptomic
modulation. Each column report samples’s fold change
along differentiation.
(XLSX)
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